United States
Nicholas J. Diamond, Ph.D. is a Shareholder at Greenberg Traurig, LLP, a global law firm of over 3,000 lawyers across 15 countries. He focuses his practice exclusively on federal and international legal matters for businesses and products regulated by the U.S. Food and Drug Administration (FDA), and similar regulators in other major international markets. He co-leads the firm’s FDA regulatory team. Nick’s regulatory practice spans research, commercialization, post-market compliance, marketing and promotion, and enforcement across all FDA-regulated products, with a primary focus on drugs, devices, and diagnostics (including digital health products). He regularly counsels clients on “high stakes” interactions with FDA, especially involving enforcement actions. His background as a trained bioethicist, combined with his experience teaching bioethics at leading academic institutions, enhances his ability to assist companies with ethical considerations that can emerge during research and product commercialization. His international regulatory practice is enhanced by his training in public international law, and includes extensive experience navigating life sciences and medical device issues in Canada, the Asia-Pacific, the European Union and United Kingdom, Latin America, and the Middle East. Nick also applies his extensive federal and international regulatory experience in the context of due diligence exercises for complex domestic and cross-border corporate transactions, especially for private equity sponsors. He has led the FDA regulatory due diligence on M&A transactions with transaction values ranging from a few million dollars to over $4 billion. Apart from his practice, Nick is a passionate educator. Since 2018, he has taught as an adjunct professor at the Georgetown University Law Center. He is also an accomplished writer whose work has been featured in leading law reviews, scholarly journals, and well-respected media publications worldwide. He holds a Ph.D. in public international law from Leiden in The Netherlands.
Nick is a Shareholder in the Healthcare & FDA Practice. He focuses on federal and international legal matters within the food, health care, life sciences, medical device, and technology sectors.
Nick currently teaches "Bioethics and Social Justice" for JD and LLM students. He has previously taught other courses, such as "Public Health Law and Ethics".
Nick sits on the Advisory Board of the Health Law & Policy Institute (HLPI) at the University of Houston Law Center. HLPI was formed in 1978 and is home to one of the nation’s leading health law programs.
Nick is a contributor to Investment Claims, an acclaimed resource from Oxford University Press for practitioners and academics working in international arbitration.
Nick is a PhD candidate in public international law at Leiden Law School, where he is writing on human rights considerations in international investment law.